GU Cancers 2024 | SURPASS: ADP-A2M4CD8 T-cell receptor T-cell therapy and pembrolizumab in UC

David Aggen, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the Phase I SURPASS trial (NCT04044859) of ADP-A2M4CD8 T-cell receptor (TCR) T-cell therapy targeting melanoma-associated antigen A4 (MAGE-A4) in advanced cancers. A new SURPASS cohort consisting of patients with urothelial cancer (UC), who received first-line cisplatin-based chemotherapy and are undergoing second-line pembrolizumab, has been enrolled. Primary endpoints include safety assessment, and secondary endpoints evaluate overall response rate. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.